medigraphic.com
ISSN 2007-6517 (Print)

2014, Number 1

<< Back Next >>

Rev Latinoam Cir 2014; 4 (1)

Lymphovascular invasion and mutated p53 as predictive factors of axillary lymph nodes metastasis in breast cancer

Sánchez MW, Vanegas SD, Mercedes MM

Language: Spanish
References: 31
Page: 10-15
PDF size: 267.45 Kb.


ABSTRACT

Introduction: Recently, it has been studied that histological factors in primary breast tumor are predictive of axillary node status. The aim of our study was to analyze the classical histological tumor factors and genetic study of the tumor suppressor gene p53 as likely predictors of metastatic axillary nodal involvement in breast cancer.
Materials and methods: This analytical study type -Factor Ex post included 100 patients diagnosed with breast adenocarcinoma, who were breast surgery was performed with axillary dissection. Histopathological analysis correlated the predictive value of lymphovascular invasion of tumor present and p53 gene mutation and the probability of axillary metastases.
Results: The average age was 54.5 years. Thirty patients with lymphatic invasion, 24 (80%) had metastases to axillary nodes. Sixteen of 70 cases without lymphatic invasion had axillary metastases (p = 0.000008). The only vascular invasion occurred in 12 patients; no statistical significant difference for axillary metastatic disease (p = 0.16). In 18 patients there was p53 gene mutation; of these, 15 had significant statistically axillary metastases (83%) (p = 0.0025). There were positive predictive value (PPV) for axillary lymph node infiltration 83.3%. In tumors without gene mutation, the correlation with the presence of the axillary metastases were not predictive.
Conclusions: Lymphatic and vascular invasion in the primary tumor associated are adverse prognostic factors associated with axillary lymph node metastases. The mutated p53 gene in the primary tumor is a PPV for axillary metastasis.


REFERENCES

  1. Howlader N, Noone AM, Krapcho M et al (eds). SEER cancer statistics review, 1975-2010 [Internet]. Bethesda, MD: National Cancer Institute; 2013. Available in: http://seer.cancer.gov/csr/1975_2010/

  2. Sánchez MW. Mortalidad por cáncer en Colombia, datos oficiales 1998 a 2008. Revista Colombiana Cirugía. 2011;26:46-47.

  3. Rincón J, Mendoza M, Vanegas D, Sánchez MW. Factores pronósticos en cáncer de mama. Foro Quirúrgico Colombiano SCC. 2001;38.

  4. Thor AD, Moore II DA. Pronostic and preventive markers in breast cancer. In Breast Cancer-ACS. B.B Deckers Inc.; 2000:113-130.

  5. Amersi F, Giuliano AE. Management of the axilla. Hematol Oncol Clin North Am. 2013;27(4):687-702.

  6. Giuliano AE, McCall L, Beitsch P et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426-432.

  7. Weidner N, Cady B, Goodson II W. Phatologic pronostic factors for patient with breast carcinoma. Surg Oncol Clin North Am. 1997;6(3):415-462.

  8. Zakaria S, Pantvaidya G, Reynolds CA et al. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different? Surgery. 2008;143(5):641-647.

  9. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1318-1327.

  10. Campbell MJ, Machin D. Medical statistics: a commonsense approach. 2nd ed. New York: John Wiley & Sons; 1996:142-145.

  11. Edge SB, Byrd DR, Compton CC et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:347-376.

  12. Mamounas EP, Anderson SJ, Dignam JJ et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30(32):3960-3966.

  13. Dings PJ, Elferink MA, Strobbe LJ, de Wilt JH. The prognostic value of lymph node ratio in node-positive breast cancer: a dutch nationwide population-based study. Ann Surg Oncol. 2013;20(8):2607-2614.

  14. Glechner A, Wockel A, Gartlehner G et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013;8:812-825.

  15. Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: a systematic review. JAMA. 2013;310(13):1385-1394.

  16. Rahman ZU, Buzdar AU, Singletary E, Hortobagy GN. Selection of systemic therapy: is axillary lymph node status important? Semin Breast Dis. 1998;1(3):157-166.

  17. Fisher B, Constantino J, Redmond C et al. A Randomized clinical trial evaluating tamoxifen in the treatment of patients with lymph node negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med. 1989;320:479-484.

  18. Mackey JR, Martin M, Pienkowski T et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14(1):72-80.

  19. Ravdin PM. Can patient and tumor characteristics allow prediction of axillary lymph node status? Semin Breast Dis. 1998;1(3):141-145.

  20. Lee AK, DeLellis RA, Silverman ML et al. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol. 1990;8(9):1457-1465.

  21. Rosen PP, Saigo PE, Braun DW et al. Occult axillary lymph node metastases from breast cancer with intramammary lymphatic tumor emboli. Am J Surg Pathol. 1982;6:636-641.

  22. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastasis in patients with T1 breast cancer. Cancer. 1997;79:1918-1922.

  23. Fein DA, Fowble BL, Hanlon AL et al. Identification of women with T1 and T2 breast cancer al low risk of positive axillary nodes. J Surg Oncol. 1997;65:34-39.

  24. Chadha M, Chabon AB, Friedman P et al. Predictors of axillary lymph node metastasis in patients with T1 breast cancer. Cancer. 1994;73:3350-3353.

  25. Thor AD, Moore DH II, Edgerton SM et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst. 1992;84:845-855.

  26. Chen YH, Cai JJ, Lu YD. The relation between p53 expression and lymph node metastasis of breast cancer. Zhonghua Zhong Liu Za Zhi. 1994;16(4):266-268.

  27. Pinto Y, Ibáñez M, Rangel N, Ramírez S, Vanegas D, Sanchez MW. Polimorfismo del gen p53 en cáncer mamario familiar en una población colombiana. Revista Colombiana de Cirugía. 2007;22(1):17-26.

  28. Rosen RR, Lesser M, Arroyo C et al. p53 in node negatives breast carcinomas: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. JCO. 1995;13:821-830.

  29. Noguchi M, Kitagawa H, Thomas M et al. The relationship of p53 protein and lymph node metastases in invasive breast cancer. Surg Today. 1994;24(6):512-517.

  30. Vojtesek B, Kovarik J, Nenutil R et al. p53 protein overexpression associates with growth patterns rather than with metastasizing in operable breast cancer. Neoplasma. 1995;42(6)331-336.

  31. Takashima T, Onada N, Ishikawa T et al. Proliferating cell nuclear antigen labeling index and p53 expression predict outcome for breast cancer patients with four or more lymph node metastases. Int J Mol Med. 2001;8(2):159-163.




2020     |     www.medigraphic.com